RecruitingPhase 2NCT04793919
Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia
Sponsor
Associazione Italiana Ematologia Oncologia Pediatrica
Enrollment
89 participants
Start Date
Oct 9, 2019
Study Type
INTERVENTIONAL
Conditions
Summary
The trial is open to all patients with a diagnosis of acute promyelocytic leukemia (APL) who are PCR-positive for the PML-RARα transcript and less than 18 years of age.
Eligibility
Max Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This study is looking at optimal treatment for children and adolescents with acute promyelocytic leukemia (APL), a specific and potentially curable type of blood cancer. APL is identified by a specific genetic change (the PML/RARα fusion gene). Researchers are tracking outcomes of children treated under a standardized protocol.
**You may be eligible if...**
- You are under 18 years old
- You have a newly confirmed diagnosis of APL with the PML/RARα genetic marker
- A parent or legal guardian has given written consent
**You may NOT be eligible if...**
- Your APL diagnosis is not confirmed by the required genetic test (PML/RARα)
- You have significant liver, kidney, or heart problems
- You have already started treatment elsewhere
Talk to your doctor to see if this trial is right for you.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGMylotarg
See the protocol
DRUGArsenic Trioxide
See the protocol
DRUGAll-trans retinoic acid
See the protocol
Locations(31)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04793919